Literature DB >> 22205110

Immunohistochemical diagnosis of Fabry nephropathy and localisation of globotriaosylceramide deposits in paraffin-embedded kidney tissue sections.

Carmen Valbuena1, Dina Leitão, Fátima Carneiro, João Paulo Oliveira.   

Abstract

Fabry disease (FD) is a rare X-linked lysosomal storage disorder of glycosphingolipids, mostly globotriaosylceramide (Gb3). Proteinuric chronic kidney disease develops frequently, and recognition of Fabry nephropathy on a kidney biopsy may be the first clue to the underlying diagnosis. Since the accumulated glycosphingolipids are largely extracted by the paraffin-embedding procedure, the most characteristic feature of Fabry nephropathy on routine light microscopy (LM) is nonspecific cell vacuolization. To test whether residual Gb3 in kidney tissue might be exploited for the specific diagnosis of Fabry nephropathy, paraffin-embedded kidney biopsies of nine FD patients (one boy, four men, four women) and of a female carrier of a mild genetic mutation, with no evidence of Fabry nephropathy, were immunostained with an anti-Gb3 antibody. The adult biopsies were additionally co-stained with a lysosomal marker (anti-lysosomal-associated membrane protein 2 (anti-LAMP2) antibody). The distribution of Gb3 deposits was scored per cell type and compared to the histological scorings of glycosphingolipid inclusions on semi-thin sections. FD patients had residual Gb3 in all types of glomerular, tubular, interstitial and vascular kidney cells. The highest expression of LAMP2 was seen in tubular cells, but there were no meaningful associations between LAMP2 expression and prevalence of Gb3 deposits on different kidney cell types. The histological scorings of glycosphingolipid inclusions were relatively higher than the corresponding immunohistochemical scorings of Gb3 deposits. In the mildly affected female, Gb3 expression was limited to tubular cells, a pattern similar to controls. Gb3 immunostaining allows the specific diagnosis of Fabry nephropathy even in kidney biopsies routinely processed for LM.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22205110     DOI: 10.1007/s00428-011-1182-y

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  26 in total

1.  FABRY'S DISEASE: CLASSIFICATION AS A SPHINGOLIPIDOSIS AND PARTIAL CHARACTERIZATION OF A NOVEL GLYCOLIPID.

Authors:  C C SWEELEY; B KLIONSKY
Journal:  J Biol Chem       Date:  1963-09       Impact factor: 5.157

2.  Fabry disease: a morphologic study of 11 cases.

Authors:  Edgar G Fischer; Michael J Moore; Donna J Lager
Journal:  Mod Pathol       Date:  2006-06-23       Impact factor: 7.842

3.  Cellular and tissue localization of globotriaosylceramide in Fabry disease.

Authors:  Milan Elleder
Journal:  Virchows Arch       Date:  2008-05-07       Impact factor: 4.064

4.  A female heterozygous patient with Fabry's disease with renal accumulation of trihexosylceramide detected with a monoclonal antibody.

Authors:  M Fukushima; Y Tsuchiyama; T Nakato; T Yokoi; H Ikeda; S Yoshida; T Kusumoto; K Itoh; H Sakuraba
Journal:  Am J Kidney Dis       Date:  1995-12       Impact factor: 8.860

5.  Verotoxins induce apoptosis in human renal tubular epithelium derived cells.

Authors:  T Taguchi; H Uchida; N Kiyokawa; T Mori; N Sato; H Horie; T Takeda; J Fujimoto
Journal:  Kidney Int       Date:  1998-06       Impact factor: 10.612

6.  Early renal changes in hemizygous and heterozygous patients with Fabry's disease.

Authors:  M C Gubler; G Lenoir; J P Grünfeld; A Ulmann; D Droz; R Habib
Journal:  Kidney Int       Date:  1978-03       Impact factor: 10.612

Review 7.  Renal ultrastructural findings in Anderson-Fabry disease.

Authors:  Adalberto Sessa; Antonella Toson; Manuela Nebuloni; Francesco Pallotti; Ferdinando Giordano; Graziana Battini; Alessia Maglio; Mietta Meroni; Gilberto Calconi; Gabriele Bertolone; Pierlucio Gatti
Journal:  J Nephrol       Date:  2002 Mar-Apr       Impact factor: 3.902

8.  X-inactivation patch size in human female tissue confounds the assessment of tumor clonality.

Authors:  Marco Novelli; Antonio Cossu; Dahmane Oukrif; Alberto Quaglia; Sunil Lakhani; Richard Poulsom; Peter Sasieni; Piera Carta; Marcella Contini; Anna Pasca; Giuseppe Palmieri; Walter Bodmer; Francesco Tanda; Nick Wright
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-27       Impact factor: 11.205

9.  Generation of one set of murine monoclonal antibodies specific for globo-series glycolipids: evidence for differential distribution of the glycolipids in rat small intestine.

Authors:  M Kotani; I Kawashima; H Ozawa; K Ogura; T Ariga; T Tai
Journal:  Arch Biochem Biophys       Date:  1994-04       Impact factor: 4.013

10.  Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy.

Authors:  Carmen Valbuena; Elísio Carvalho; Manuela Bustorff; Mariana Ganhão; Sandra Relvas; Rosete Nogueira; Fátima Carneiro; João Paulo Oliveira
Journal:  Virchows Arch       Date:  2008-09-04       Impact factor: 4.064

View more
  6 in total

1.  Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma.

Authors:  Susana Ferreira; Christiane Auray-Blais; Michel Boutin; Pamela Lavoie; José Pedro Nunes; Elisabete Martins; Scott Garman; João Paulo Oliveira
Journal:  Clin Chim Acta       Date:  2015-06-09       Impact factor: 3.786

2.  The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies.

Authors:  Susana Ferreira; Alberto Ortiz; Dominique P Germain; Miguel Viana-Baptista; António Caldeira-Gomes; Marta Camprecios; Maria Fenollar-Cortés; Ángel Gallegos-Villalobos; Diego Garcia; José Antonio García-Robles; Jesús Egido; Eduardo Gutiérrez-Rivas; José Antonio Herrero; Sebastián Mas; Raluca Oancea; Paloma Péres; Luis Manuel Salazar-Martín; Jesús Solera-Garcia; Helena Alves; Scott C Garman; João Paulo Oliveira
Journal:  Mol Genet Metab       Date:  2014-11-09       Impact factor: 4.797

3.  Characterization and phosphoproteomic analysis of a human immortalized podocyte model of Fabry disease generated using CRISPR/Cas9 technology.

Authors:  Ester M Pereira; Anatália Labilloy; Megan L Eshbach; Ankita Roy; Arohan R Subramanya; Semiramis Monte; Guillaume Labilloy; Ora A Weisz
Journal:  Am J Physiol Renal Physiol       Date:  2016-09-28

4.  Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease.

Authors:  Nurcan Üçeyler; Nils Schröter; Waldemar Kafke; Daniela Kramer; Christoph Wanner; Frank Weidemann; Claudia Sommer
Journal:  PLoS One       Date:  2016-11-16       Impact factor: 3.240

5.  Fabry Disease With Concomitant Lewy Body Disease.

Authors:  Kelly Del Tredici; Albert C Ludolph; Simone Feldengut; Christian Jacob; Heinz Reichmann; Jürgen R Bohl; Heiko Braak
Journal:  J Neuropathol Exp Neurol       Date:  2020-04-01       Impact factor: 3.685

Review 6.  Developments in the treatment of Fabry disease.

Authors:  Sanne J van der Veen; Carla E M Hollak; André B P van Kuilenburg; Mirjam Langeveld
Journal:  J Inherit Metab Dis       Date:  2020-03-02       Impact factor: 4.982

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.